IBB vs. IDNA
IBB (iShares Nasdaq Biotechnology ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds from iShares - IBB tracks the NASDAQ Biotechnology Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 5 years, IBB returned 2.10%/yr vs -8.42%/yr for IDNA. Their correlation of 0.90 suggests significant overlap in exposure. Both charge a 0.47% expense ratio.
Performance
IBB vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IBB achieves a -0.68% return, which is significantly lower than IDNA's 10.31% return.
IBB
- 1D
- 1.97%
- 1M
- -1.56%
- YTD
- -0.68%
- 6M
- -2.57%
- 1Y
- 34.50%
- 3Y*
- 9.40%
- 5Y*
- 2.10%
- 10Y*
- 6.23%
IDNA
- 1D
- 0.73%
- 1M
- -2.56%
- YTD
- 10.31%
- 6M
- 8.52%
- 1Y
- 40.87%
- 3Y*
- 6.74%
- 5Y*
- -8.42%
- 10Y*
- —
IBB vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | -0.68% | 27.98% | -2.41% | 3.76% | -13.69% | 0.95% | 26.01% | 16.05% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 10.31% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
Correlation
The correlation between IBB and IDNA is 0.89, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.89 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.88 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.90 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.90 |
The correlation between IBB and IDNA has been stable across timeframes, ranging from 0.88 to 0.90 - a consistent structural relationship.
IBB vs. IDNA - Sectors Allocation Comparison
Sectors
IBB
IDNA
Healthcare
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
IBB
IDNA
Basic Materials
IBB
-
IDNA
-
Communication Services
IBB
-
IDNA
-
Consumer Cyclical
IBB
-
IDNA
-
Consumer Defensive
IBB
-
IDNA
-
Energy
IBB
-
IDNA
-
Financial Services
IBB
-
IDNA
-
Industrials
IBB
-
IDNA
Real Estate
IBB
-
IDNA
-
Technology
IBB
-
IDNA
-
Utilities
IBB
-
IDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IBB vs. IDNA — Risk / Return Rank
IBB
IDNA
IBB vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBB | IDNA | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.74 | 1.68 | +0.07 |
Sortino ratioReturn per unit of downside risk | 2.50 | 2.44 | +0.07 |
Omega ratioGain probability vs. loss probability | 1.30 | 1.27 | +0.02 |
Calmar ratioReturn relative to maximum drawdown | 3.60 | 3.85 | -0.25 |
Martin ratioReturn relative to average drawdown | 11.43 | 10.98 | +0.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IBB | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.74 | 1.68 | +0.07 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.10 | -0.30 | +0.39 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.27 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.26 | 0.10 | +0.16 |
Drawdowns
IBB vs. IDNA - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBB and IDNA.
Loading charts...
Drawdown Indicators
| IBB | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.85% | -68.26% | +5.41% |
Max Drawdown (1Y)Largest decline over 1 year | -9.63% | -10.66% | +1.03% |
Max Drawdown (3Y)Largest decline over 3 years | -24.85% | -29.73% | +4.88% |
Max Drawdown (5Y)Largest decline over 5 years | -39.82% | -68.26% | +28.44% |
Max Drawdown (10Y)Largest decline over 10 years | -39.82% | — | — |
Current DrawdownCurrent decline from peak | -5.64% | -45.61% | +39.97% |
Average DrawdownAverage peak-to-trough decline | -21.18% | -36.24% | +15.06% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.03% | 3.73% | -0.70% |
Volatility
IBB vs. IDNA - Volatility Comparison
iShares Nasdaq Biotechnology ETF (IBB) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) have volatilities of 6.86% and 7.18%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IBB | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.86% | 7.18% | -0.32% |
Volatility (6M)Calculated over the trailing 6-month period | 15.38% | 17.98% | -2.60% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.89% | 24.48% | -4.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.99% | 28.42% | -6.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.22% | 29.53% | -6.31% |
IBB vs. IDNA - Expense Ratio Comparison
Both IBB and IDNA have an expense ratio of 0.47%.
Dividends
IBB vs. IDNA - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.23%, less than IDNA's 1.07% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.07% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
IBB and IDNA have a correlation of 0.89, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IDNA has higher volatility (7.18%) compared to IBB (6.86%). In terms of maximum drawdown, IBB dropped -62.85% vs IDNA's -68.26%.
On 5-year performance, IBB leads with 2.10% vs -8.42% for IDNA. Both ETFs have the same 0.47% expense ratio. On volatility, IBB has been the lower-risk option at 6.86%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, IBB has performed better with a 2.10% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IBB and IDNA have the same expense ratio: 0.47% per year.
IDNA has the higher dividend yield at 1.07%, compared with 0.23% for IBB.
IBB tracks NASDAQ Biotechnology Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index.
IBB currently has the higher Sharpe Ratio (1.74 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IBB and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer